Kura Oncology (KURA) Depreciation & Amortization (CF) (2023 - 2026)

Kura Oncology has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $355000.0 for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 47.3% to $355000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2026, up 42.01% year-over-year, with the annual reading at $1.0 million for FY2025, 29.0% up from the prior year.
  • Depreciation & Amortization (CF) was $355000.0 for Q1 2026 at Kura Oncology, down from $403000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $403000.0 in Q4 2025 and troughed at $156000.0 in Q4 2024.
  • The 4-year median for Depreciation & Amortization (CF) is $213000.0 (2023), against an average of $229769.2.
  • The largest YoY upside for Depreciation & Amortization (CF) was 158.33% in 2025 against a maximum downside of 21.15% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $165000.0 in 2023, then decreased by 5.45% to $156000.0 in 2024, then skyrocketed by 158.33% to $403000.0 in 2025, then dropped by 11.91% to $355000.0 in 2026.
  • Per Business Quant, the three most recent readings for KURA's Depreciation & Amortization (CF) are $355000.0 (Q1 2026), $403000.0 (Q4 2025), and $164000.0 (Q3 2025).